Necrostatin 2 racemate
(Synonyms: 5-[(7-氯-1H-吲哚-3-基)甲基]-3-甲基-2,4-咪唑烷二酮,Necrostatin 1S; Nec-1S; 7-Cl-O-Nec1) 目录号 : GC36711
Necrostatin 2 racemate是一种不影响吲哚胺2,3-双加氧酶（IDO）活性的，具有高度特异性的受体相互作用蛋白激酶1（RIPK1）抑制剂。
Cas No.:852391-15-2
Sample solution is provided at 25 µL, 10mM.
Necrostatin 2 racemate is a highly specific receptor-interacting protein kinase 1 (RIPK1) inhibitor that does not affect indoleamine 2,3-dioxygenase (IDO) activity[1]. Necrostatin 2 racemate is commonly used in research on inflammatory diseases (such as rheumatoid arthritis), neurodegenerative diseases (such as Alzheimer's disease and Parkinson's disease), and organ protection[2, 3].
In vitro, treatment of pro-B exosomes+ lymphocytes with Necrostatin 2 racemate (1μM) for 48h significantly enhanced cytosporone B (10μM)-induced apoptosis, resulting in an average apoptosis rate of 63.14%, which was approximately 628% higher than that of the control group (10%)[4]. Pretreatment of wild-type bone marrow-derived macrophages (BMDMs) with Necrostatin 2 racemate (45μM), followed by co-treatment with heme and Pam3CSK4 (Pam3) for 48h, partially inhibited heme- and Pam3-induced cell death; this protective effect was further enhanced when combined with z-VAD-FMK (zVAD)[5]. Co-treatment of A549 and H358 cells with Necrostatin 2 racemate (10μM) and copper-based metal-organic frameworks (Cu-MOF) for 72h significantly reversed Cu-MOF-induced cytotoxicity and partially restored cell viability[6].
In vivo, daily intraperitoneal administration of Necrostatin 2 racemate (1.6mg/kg/day) in apolipoprotein E-deficient (ApoE-/-) mice, starting from angiotensin II (Ang II) infusion and continuing for 28 days, significantly alleviated abdominal aortic aneurysm (AAA) formation and reduced AAA incidence[7]. Daily intraperitoneal administration of Necrostatin 2 racemate (2mg/kg/day; once daily) in a neonatal mouse model of necrotizing enterocolitis (NEC), starting from NEC induction and continuing for 3 days, significantly improved survival rates, alleviated intestinal histopathological damage, and reduced the expression of pro-inflammatory cytokines (IL-1β, IL-17, TNF-α, and IFN-γ)[8].
References:
[1] YU J, ZHONG B, ZHAO L, et al. Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors Necrostatin-1 (Nec-1) and 7-Cl-O-Nec-1 (Nec-1s) are potent inhibitors of NAD(P)H: Quinone oxidoreductase 1 (NQO1)[J]. Free Radical Biology and Medicine, 2021, 173: 64-69.
[2] YU Z, JIANG N, SU W, et al. Necroptosis: a novel pathway in neuroinflammation[J]. Frontiers in Pharmacology, 2021, 12: 701564.
[3] MIFFLIN L, OFENGEIM D, YUAN J. Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target[J]. Nature Reviews Drug Discovery, 2020, 19(8): 553-571.
[4] GENTIMIR C A, GELEŢU G, CHELARU L, et al. Biochemical effects of TLRs, CXCL12, and necrosome activation on pro-B lymphocyte apoptosis in the presence of fibroblasts[J]. Romanian Journal of Oral Rehabilitation, 2022, 14(3).
[5] SUNDARAM B, PANDIAN N, MALL R, et al. NLRP12-PANoptosome activates PANoptosis and pathology in response to heme and PAMPs[J]. Cell, 2023, 186(13): 2783-2801.
[6] LI K, WU L, WANG H, et al. Apoptosis and cuproptosis co-activated copper-based metal-organic frameworks for cancer therapy[J]. Journal of Nanobiotechnology, 2024, 22(1): 546.
[7] WANG Q, ZHOU T, LIU Z, et al. Inhibition of Receptor-Interacting Protein Kinase 1 with Necrostatin-1s ameliorates disease progression in elastase-induced mouse abdominal aortic aneurysm model[J]. Scientific Reports, 2017, 7(1): 42159.
[8] LIU T, ZONG H, CHEN X, et al. Toll-like receptor 4-mediated necroptosis in the development of necrotizing enterocolitis[J]. Pediatric Research, 2022, 91(1): 73-82.
Necrostatin 2 racemate是一种不影响吲哚胺2,3-双加氧酶（IDO）活性的，具有高度特异性的受体相互作用蛋白激酶1（RIPK1）抑制剂[1]。Necrostatin 2 racemate通常用于炎症性疾病（如类风湿性关节炎）、神经退行性疾病（如阿尔茨海默病和帕金森病）和器官保护的研究[2,3]。
在体外，Necrostatin 2 racemate（1μM）处理pro-B exosomes+淋巴细胞48h，显著增强了由cytosporone B（10μM）诱导的细胞凋亡，凋亡率平均达到63.14%，较对照组（10%）提高约628%[4]。Necrostatin 2 racemate（45μM）预处理野生型骨髓来源巨噬细胞（BMDMs）后，与血红素和Pam3CSK4 (Pam3)共处理48h，可部分抑制由血红素和Pam3诱导的细胞死亡；当与z-VAD-FMK（zVAD）联用时可进一步增强保护作用[5]。Necrostatin 2 racemate（10μM）与铜金属有机骨架（Cu-MOF）共同处理A549和H358细胞72h，能显著逆转由Cu-MOF诱导的细胞毒性，部分恢复细胞活力[6]。
在体内，Necrostatin 2 racemate（1.6mg/kg/day）通过腹腔注射处理载脂蛋白E缺陷（ApoE-/- ）小鼠，从血管紧张素II（Ang II）灌注开始，持续28天，显著减轻了腹主动脉瘤（AAA）的形成，并降低了AAA发生率[7]。Necrostatin 2 racemate（2mg/kg/day; once daily）通过腹腔注射治疗坏死性小肠结肠炎（NEC）模型新生小鼠，从NEC诱导开始持续3天，显著提高了小鼠的生存率，减轻了肠道组织病理损伤，并降低了促炎细胞因子（IL-1β、IL-17、TNF-α和IFN-γ）的表达[8]。
| Cell experiment [1]: | |
Cell lines | BMDMs (bone marrow-derived macrophages) |
Preparation Method | BMDMs were treated with a combination of 45μM Necrostatin 2 racemate (with or without zVAD), heme, and Pam3 for 48h, and the kinetics of cell death were monitored using the IncuCyte S3 or SX5 live-cell analysis system. |
Reaction Conditions | 45μM; 48h |
Applications | Necrostatin 2 racemate treatment partially reduced cell death in response to heme plus Pam3, compared with PBS control, and the addition of zVAD further reduced the cell death. |
| Animal experiment [2]: | |
Animal models | ApoE-/- mice (apolipoprotein E-deficient mice) |
Preparation Method | ApoE-/- mice received osmotic pumps that disbursed Ang II at 1000ng/kg/min. Daily injection of Necrostatin 2 racemate (1.6mg/kg/day; i.p.) started immediately following the pump implantation. Mice were euthanized 28 days after. The external aortic diameter was measured at the region showing maximum dilation with a digital caliper. Aneurysm incidence is defined as an increase of 50% or greater in the external width of the suprarenal aorta as compared with that of the infrarenal region. |
Dosage form | 1.6mg/kg/day; 28 days; i.p. |
Applications | Compared to the DMSO group, Necrostatin 2 racemate-treated mice showed significantly alleviated aneurysm formation, reflected by a much smaller aortic dilatation (Nec-1s: 55.40 ± 13.08% vs. DMSO: 121.1 ± 16.44%, P < 0.05) as well as a reduced AAA incidence (from 90.5% to 33.3%). |
References: | |
| Cas No. | 852391-15-2 | SDF | |
| 别名 | 5-[(7-氯-1H-吲哚-3-基)甲基]-3-甲基-2,4-咪唑烷二酮,Necrostatin 1S; Nec-1S; 7-Cl-O-Nec1 | ||
| Canonical SMILES | ClC1=C2C(C(CC3C(N(C)C(N3)=O)=O)=CN2)=CC=C1 | ||
| 分子式 | C13H12ClN3O2 | 分子量 | 277.71 |
| 溶解度 | DMSO: ≥ 50 mg/mL (180.04 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.6009 mL | 18.0044 mL | 36.0088 mL |
| 5 mM | 720.2 μL | 3.6009 mL | 7.2018 mL |
| 10 mM | 360.1 μL | 1.8004 mL | 3.6009 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet